Indi Molecular said this week that it has raised $300,000 from a new investor, Asset Management Ventures, bringing the total amount raised in its seed round to $1.8 million.

The company plans with this funding to continue development of its protein catalyzed capture reagents, a synthetic affinity agent technology that it hopes to position as an alternative to traditional antibodies.